en
E-mail us

Application of Granularity Analysis in Crystal Typing Research

This article series is initiated and compiled by the Crystalline Cloud Solid-State Testing Center. Its aim is to create a platform for exchange and learning among industry peers. We intend to explore and share systematic applications of various solid-state characterizations, delve into the significance of test results and data, discuss and solve the various issues encountered in characterization testing. Our goal is to provide solutions and insights for challenges encountered during drug crystallization research and development.


Content Overview


1. Introduction


2. Applications of Laser Particle Size Analyzer


2.1 Laser Diffraction Method


2.2 Wet/Dry Methods


3. Development of Particle Size Distribution Methods


3.1 Development of Wet Methods


3.2 Development of Dry Methods


3.3 Method Validation


4. Testing Considerations


5. Conclusion


Introduction


In the process of pharmaceutical development, the particle size distribution of raw materials can significantly impact the performance of the final product, including aspects like solubility, bioavailability, uniformity of content, stability, and more. Ultimately, this can affect the safety, efficacy, and quality of the medication. Particle size distribution (PSD) has become an essential testing parameter in the quality control of active pharmaceutical ingredients (APIs) and pharmaceutical formulations.


Particle size distribution reflects the percentages of particles in different size ranges and is measured using various methods, including microscopy, sieving, sedimentation, centrifugation, dynamic light scattering, and laser diffraction. Laser diffraction, due to its speed, convenience, and minimal sample requirement, has become a commonly used method for particle size analysis.


Applications of Laser Diffraction Particle Size Analysis



The principle of laser diffraction particle size analysis


Laser diffraction particle size analyzers determine the particle size distribution of a sample by measuring the scattering of a monochromatic laser beam when it interacts with the particles. The energy distribution of the scattered light is related to the particle sizes. By measuring the energy distribution (scattering angles) of the scattered light and applying Mie scattering theory and the Fraunhofer approximation, particle size distributions can be calculated. The measurement range can span from 0.02 to 3500 μm.

crystalpharmatech-2023913-49.png

Particle Size Distribution


Equivalent spherical diameter is a measure of the size of a particle by measuring some characteristic of the particles and representing their size in terms of the diameter of a sphere that has the same characteristic. It's important to note that different particle size measurement methods can yield different equivalent spherical diameters, such as volume-equivalent spherical diameter, weight-equivalent spherical diameter, surface area-equivalent spherical diameter, and so on.

crystalpharmatech-2023913-50.png

In a particle size distribution chart, the ideal state is represented by a normal distribution curve. The X-axis (horizontal axis) represents various particle sizes, and the Y-axis corresponds to the percentage of content. The closer the particle size distribution chart is to a normal distribution, the more uniform the particle distribution, indicating better usability.


The most commonly used characteristic values for particle size distribution are cumulative distribution values, Dv10, Dv50, Dv90, with Dv50 being the median. Additionally, depending on the characteristics of the sample particles, surface area mean D[3,2] and volume mean D[4,3] can also be used as characteristic values for particle size distribution.



Depending on the dispersion medium used, particle size distribution testing can be divided into wet methods (where the dispersion medium is a liquid) and dry methods (where the dispersion medium is a gas). The choice between wet and dry methods should be based on the physicochemical properties of the sample.


Wet Method & Dry Method


Wet Method: This involves dispersing the sample in a suitable medium and is suitable for determining samples that are suspended or insoluble in the dispersing medium.


Dry Method: This method disperses the sample using compressed air, and the dispersion efficiency is directly related to the pressure settings. Dry methods are suitable for determining water-soluble samples or samples without a suitable dispersing medium.


Developing Particle Size Distribution Method



The development of wet methods for particle size distribution testing involves addressing the following issues:

crystalpharmatech-2023913-52.png



Representative Sampling


Representative sampling is crucial to ensure test reproducibility, as the sampled portion must accurately represent the entire sample, especially for samples with larger particles (>70μm). If the sampling is not representative, measurement deviations of up to 20% can occur.


Choice of Dispersing Medium


The selection of an appropriate dispersing medium is critical in wet methods. When choosing a dispersing medium, multiple factors need to be considered:



Based on different polarities, dispersing media can be categorized into five types: long-chain aliphatics like dodecane, mineral oil, sunflower oil, and palm oil; aliphatics like n-hexane, n-heptane, isooctane, and cyclohexane; alcohols like methanol, ethanol, and isopropanol; organic acids like acetic acid; and the most commonly used, water, which is transparent, cost-effective, environmentally friendly, and can mitigate the impact of temperature gradients caused by organic solvents.


Selection of Additives


To reduce surface tension, enhance wetting, and prevent re-agglomeration, a small amount of surfactant may be added when necessary. The choice of surfactant depends on the surface chemistry of the particles and the properties of the dispersing medium. Common non-ionic surfactants include Tween and Span; cationic surfactants include SDS; and anionic surfactants include CTAB.


To avoid re-agglomeration, precipitation, or coagulation of the dispersed sample, a dispersing agent may be added in small amounts to assist dispersion through mechanisms such as electrostatic stabilization, steric hindrance, and electrosteric stabilization. Examples include sodium hexametaphosphate, ammonium citrate, and sodium pyrophosphate.


Measurement Condition Setup


Measurement conditions in wet methods primarily involve the pump/stirrer speed, sample concentration, and ultrasonication.


Pump/Stirrer Speed


The pump/stirrer speed is determined by observing changes in particle size measurements as a function of the pump/stirrer speed. In general, an appropriate speed ensures that the sample enters the measurement cell uniformly and continuously, leading to reproducible results. At low speeds, larger particles in the sample may not suspend well, resulting in underestimated particle sizes. As the speed increases, proper suspension of particles is achieved, and the particle size stabilizes. At this point, the measured particle size closely matches the actual value. However, it is essential to note that high speeds may lead to the formation of bubbles, especially in emulsion samples.


Sample Concentration


Sample concentration is primarily determined based on optical density. If the sample concentration is too low, it may not be representative or may have poor signal-to-noise ratios. Conversely, a very high sample concentration can lead to multiple scattering phenomena, causing underestimated measurements. For small particle samples (particle size less than 10μm), the optical density should be less than 10%. For larger particle samples, the optical density should be in the range of 8% to 20%.


Ultrasonication


Ultrasonication can be used to disperse solid particles. The optimal ultrasonication parameters can be determined by monitoring changes in particle size with varying ultrasonication time or intensity. It is essential to note that if the optical density rapidly decreases after initial wetting, it may indicate that the sample component has dissolved in the dispersing medium, necessitating a change to a more suitable dispersing medium. If the particle size continues to decrease with prolonged ultrasonication, it suggests that particle breakage may be occurring. In the case of emulsion testing, ultrasonication is not required as it can promote further emulsification.


Development of Dry Methods


The development of dry methods for particle size distribution testing should consider sample properties, representative sampling, and measurement condition setup.

crystalpharmatech-2023913-53.png


Sample Properties


Sample properties suitable for dry method testing include the following criteria: ease of dispersion through airflow, appropriate sample brittleness (not easily broken), and non-toxicity.


Representative Sampling


Similar to wet method testing, ensuring representative sampling is essential for test reproducibility.


Measurement Condition Setup


The measurement conditions in dry methods mainly include dispersing pressure, Venturi tube type, and sample injection rate.


Dispersing Pressure


The dispersing airflow pressure can be determined by observing changes in particle size measurements as a function of dispersing airflow pressure. Going from high to low pressure, the platform pressure for particle size separation is selected. The ease of particle dispersion depends on the particle size. As particle size decreases, the relative adhesive forces between particles increase. In general, smaller particle samples (particle size less than 10μm) tend to aggregate more and are more challenging to disperse, while larger particle samples (particle size greater than 10μm) aggregate less and are easier to disperse.


Venturi Tube Type


The choice of Venturi tube type depends on sample characteristics. Standard Venturi tubes are chosen for fragile samples, while small particles, especially those that are prone to sticking and agglomerating (easily fractured samples), should use high-energy Venturi tubes to increase collision opportunities and improve dispersion.


Sample Injection Rate


The sample injection rate is adjusted through parameters like injection vibration speed, the type of injection plate, and optical density setting (filtration of optical density). Optimizing the injection rate ensures continuous and stable sample flow while maintaining optical density within an appropriate range. If the optical density is too low, the signal-to-noise ratio may be insufficient. Conversely, excessively high optical density can weaken dispersion effects and potentially introduce false peaks. For small particle samples, the optical density typically ranges from 0.5% to 3%, while for other samples, it falls within the range of 0.5% to 6%.



Relative to the validation of other analytical methods, the validation requirements for laser diffraction particle size distribution testing are relatively straightforward. They primarily include ruggedness and precision (repeatability and intermediate precision), with some variations in the ruggedness requirements between dry and wet methods. Various pharmacopeias, such as USP <429>, EP 2.9.13, Chinese Pharmacopoeia 2020, and ISO 13320:2020, specify precision validation requirements, with the relative standard deviation (RSD) needing to meet specified criteria.


Testing Considerations


Based on Crystal Cloud's 12 years of experience in pharmaceutical solid-state research, the following summary and sharing of testing considerations for Particle Size Distribution (PSD) testing are provided:



The results of particle size testing are influenced by various factors, including the properties of the sample itself. In addition to the instrument and method used, the solid-state properties of the sample will also affect the testing results.


In practice, the particle sizes in the tested sample are rarely entirely consistent. Therefore, whether large and small particles in the sample can be mixed uniformly will directly determine the representativeness of sampling and adding samples by the experimenter. If the mixing is not uniform, large particles tend to settle at the bottom of the container. If only the upper layer of particles is taken for testing, there will be significant differences between the test results and the actual situation. The wider the particle size distribution in the sample, the more challenging it is to ensure representativeness in sampling.


In another scenario, if a significant portion of large particles in the sample results from aggregation and there is no effective reduction in aggregation, each test may collect intermediates of poorly dispersed particles. This will affect the repeatability of the test results.



During the testing process, observation is essential to assess the sampling status and determine if the sample is representative. Before testing, observe whether there are significant phenomena such as aggregation, clumping, or uneven particle size distribution in the sample. During the pre-dispersion of the sample in the dispersing medium, further observation should be made to check if large particles settle at the bottom. During the sample addition process, the sample container should be rinsed multiple times to ensure that large particles are introduced into the sampler.


In addition to sampling, the choice of an appropriate dispersing medium and its ability to effectively disperse the sample are also critical factors affecting test results. When pre-dispersing the sample, observe the dispersion efficiency of the dispersing medium.

crystalpharmatech-2023913-54.png


Left: The sample is prone to foaming, which can lead to the inclusion of bubbles as sample particles during testing, affecting the results.


Middle: The particles tend to settle, indicating poor dispersion.


Right: Good dispersion of particles with no significant settling, bubbling, or non-wettability issues.


Pharmacopeial particle size testing methods include microscopy, sieving, and laser diffraction. However, the particle size results obtained from different methods are usually not directly comparable. Laser diffraction instruments approximate the sample particles as spheres of equal volume and then calculate the diameter of these spheres to obtain particle size distribution results. Real-world samples are almost never perfectly spherical, so the instrument uses mathematical models to perform the fitting and calculations. Microscopy involves visually counting the proportion of particles within a certain field of view. Sieving separates particles based on sieve mesh size and calculates the weight percentage of particles within the target size range.


crystalpharmatech-2023913-55.png

Indeed, the different methods for particle size analysis have distinct principles and calculation formulas, leading to variations in particle size data between these methods. Therefore, when comparing particle size results for a sample, it is essential to ensure consistency in the methods used.



When conducting initial particle size distribution (PSD) testing for a sample, especially if it is expected to be insoluble in the dispersing medium, it is recommended to start with wet particle size testing. Sample aggregation is a common issue, and wet testing can be used to aid dispersion with the help of a dispersing medium. Additionally, ultrasonication can be employed to further improve dispersion. This approach generally achieves better dispersion, avoiding the negative impact of aggregation, and is suitable for rapidly testing a sample for the first time.

crystalpharmatech-2023913-56.png

It's important to note that if the dispersing medium cannot effectively disperse the particles, ultrasonication may lead to particle aggregation. In such cases, the data obtained before ultrasonication may not accurately represent the true particle size of the sample. In such situations, it may be necessary to develop an appropriate particle size distribution (PSD) method specifically tailored to analyze that particular sample.



PSD, as a particle size characterization technique, can be used in conjunction with various other techniques to collectively characterize the properties of sample particles. For example, it can be combined with Polarized Light Microscopy (PLM). PLM provides a visual display of the approximate morphology, particle size, and the presence of particle aggregation, which can assist in PSD characterization.


As shown in the figure below, PLM reveals the evident presence of particle aggregation in the sample. When combined with PSD results, it becomes apparent that the particle size of the sample decreases after ultrasonication. This reduction in particle size is attributed to the disruptive effect of ultrasonication on particle aggregation. Consequently, the particle size measurements obtained after ultrasonication more closely represent the true state of the sample.

crystalpharmatech-2023913-57.png

Conclusion


The study of pharmaceutical polymorphism is essential throughout various stages of drug substance and formulation research. Particle size analysis is an indispensable characterization technique in polymorphism research. At the Crystalline Cloud Solid-State Testing Center, we have multiple Particle Size Distribution (PSD) instruments, including the Mastersizer 3000 and Microtrac S3500, to provide our partners with fast and accurate PSD characterization. We are also equipped to assist in method development and validation work, contributing to the research and development of crystalline pharmaceuticals.

Quick Links
Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
U.S
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China, 215123
Solid Form Screening Solid Form Developability Evaluation Absolute Structure Determination Crystallization Process Development The Purpose Behind Molecules to Medicine Repurposing Dexmedetomidine into an Oral Sleep-Enhancing Medication The Role of Collaboration in Optimizing the Development of HIF Inhibitors for the Treatment of Advan Mol2Med™ Integrated Services AAPS 2024 PHarmSCi 360 Concerned about mRNA -LNP Integrity during International Shipping? Improving the Manufacture of mRNA Biologics Home Formulation Development Solid Form Screening and Selection Our Company Talent Recruitment Case Study 1: Indinavir - Early Salt Form Change The Tiny-TIM System Technical Articles Solid Form Research Engineering Cocrystal Solubility and Streamlining Cocrystal Early Development The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C Biologics CMC Analytical Services High-Resolution Mass Spectrometry Crystal Pharmatech Formulation Forum News & Events Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes Unlocking the Power of AI in Pharmaceutical Development Formulation & Delivery US 2024 Concerned about mRNA -LNP Integrity during International Shipping? Analytical Techniques to Assess the mRNA 5' Cap Small Molecule Solid-State Characterization/FAST Conventional Oral Solid Dosage Forms Our History News Our Business Case Study 2: DPC 961 – Form Change On A Fast Track Compound Detecting and Avoiding Disappearing Polymorph Cases by Crystal Structure Prediction Presentations Preclinical and Tox Formulation Development Synthonic Engineering: Tools for the Rational Design of High Quality Pharmaceuticals Polymorphism of Drugs - Can We Exploit Physical Form in the Development of Low Solubility Molecules? Bioanalysis and Biomarker Services 2023-Mol2Med™ First-Time-Right Approach Webinar Series Date: 2:00-3:00 pm EDT, Wednesday, Watch on-demand
Developability Assessment Oral Solid Dosage Forms Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying CATUG and Crystal Bio Establish Strategic Partnership, Launching “CATUG-Crystal” Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services Characterization and Evaluation of Amorphous Solid Dispersion - Part 2 ADME Simulations: Insights into Bioavailability and Pharmacokinetics Utilizing Compaction Simulation for Advancing Oral Dosage Formulation Design Critical Quality Attribute (CQA) in Antibody Drug Conjugate (ADC) Modality The 16th Drug Discovery Strategic Summit (DDSS) - San Francisco Bioanalytical and Biomarker Services Single Crystal Growth & Structure Determination Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides Our People Events Case Study 3: Atorvastatin - Crystalline Form Change In Late Development Selecting the Right API Form and Formulation Instrumentation for Electron Diffraction, Applications, and Case Studies Case Studies Effective Development of API Crystallization Processes During Drug Development Efficient Preclinical Formulation Development for Poorly Soluble Compounds pKa/LogP/LogD Measurements Date: 2:00-3:00 pm EDT, Wednesday, Watch on-demand
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion) Dr. LianFeng Huang Joins Crystal Pharmatech as Chief Scientist Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1 Characterization and Evaluation of Amorphous Solid Dispersion-Part 2 Parameter Sensitivity with GastroPlus Critical Quality Attribute D0 Impact in ADC Modality SAPA Annual Conference (Gold Corporate Sponsorship) Crystal Bio Solutions Bio Analytics API Form and Solid-State Research Crystallization Development Mini-tablet Knowledge Hub Molecules-to-Medicine: Accelerating Drug Development through Collaboration PBPK in Preclinical/FIH Scenarios Whitepaper Case Study 4: Gatifloxacin - Crystalline Form Changes With A Licensed Compound Amorphous Solid Dispersions Using Thermodynamic Phase Maps in API Crystallization Process Design Pre-clinical Formulation Strategies Sponsored by Crystal Pharmatech Date: 2:00-3:00 pm EDT, Wednesday, Whatch on-demand
Stability and Solubility Studies Comprehensive Physicochemical Property Evaluation Pediatric Formulation (Mini-tablet) Crystal Formulation Services successfully passed the dual certification of GMP and GDP conducted by SGS Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions Assessment of CQA in mRNA-LNP Modality Overcoming Bioavailability Barrier to Deliver Protein Degraders 14th American Drug Delivery and Formulation Summit (Exhibit) Developability Assessment, Pre-formulation Study for IND Enabling Product Quality Analysis Additional Capabilities Chiral Separation Technology Our Partner Advanced Characterization: Tools for Accelerating Molecules to Medicine Tools for Accessing New Solid Forms Case Study 5: Lifecycle Management - Olanzapine - Crystalline Change From Free Acid to Salt Enabling Poorly Soluble Weak Bases for Improved Bioavailability: Why a Salt May Not be the Best Choice Integrated Phase and Formulation Selection to Support GLP Toxicology and First in Human Studies Sponsored by Crystal Pharmatech In-Silico PBPK Modeling and Simulation Industry Shift: FDA Goes Vegan? Date: 2:00-3:00 pm EDT, Wednesday,Watch on-demand
Crystallization Development Services Excipient Selection and Compatibility Studies Analytical Chemistry ASD Series Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying Overcoming Poor Solubility and Dissolution of Insoluble Molecules Patent Analysis of Resmetirom Sterility Assays in Drug/Device Manufacturing 2024 CASSS - Mass Spec Symposium Flow Cytometry About Us Pre-formulation Studies Formulations for PK/Efficacy/Tox Studies Crystallization and Spray Drying Process Development, Scale-Up, and Technology Transfer Case Study 6: Oxybutynin- Crystalline Change From Salt to Free Base Learn about Drug Eutectic Screening Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving the Important Milestone in Formulation Capability Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023 Biologics ChemOutsourcing 2024 Crystal Bio Webinar ELISpot Assays Solid-State NMR Analysis Resources Avoiding Drug Failures: Right First Time; Fast First Time Exploring the Pharmaceutical Solid State by Molecular Simulation Crystallization Process Method SMART Development of Pre-clinical Candidates Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services Formulation and Analytical Development Animal Dosing Vehicle Selection Detecting Low-Level Crystallinity in ASD-like Samples Using ssNMR Techniques Understand ASD Manufacturing Strategies, Choose the Optimal One Immuno-Oncology Summit 2024 - Meet Crystal Bio at Booth 15 Molecular Biology Clinical and Commercial Manufacturing Amorphous Solid Dispersions Careers Tools and Strategies for De-risking Rapid Drug Substance and Drug Product Development API Crystallization Crystal Pharmatech Returned to AAPS 2022 PharmSci 360 Fun Sharing: The Secret Behind the Silky Smoothness of Chocolate (Part 2) GMP Manufacturing A Brief Introdction to Amorphous Solid Dispersion Technology Amorphous Solid Dispersions: Two Heads Are Better Than One FIH-PMF-FMF Manufacturing The Bioprocessing Summit 2024 - Meet Crystal Bio at Booth T13 Contact Us Crystal Pharmatech and Particle Sciences Form a US-China Pharmaceutical CRO Partnership Advancements in Analytical Tools for API and DP Characterization Co-crystals Fun Sharing: The Secret behind the Silky Smooth Enjoyment of Chocolate (Part 3) Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs Meet Crystal Pharmatech at 2024 Controlled & Modified Drug Release Summit Assessment of Powder Segregation in Direct Compression (DC) Blends: Developing Predictive and PAT Tools Search Result Webinar Series Crystal Pharmatech Raises $10 Million to Accelerate Growth Solid Forms: The Good; The Bad; The Ugly Impact of Solid-state in Early Development Fun Sharing: The Secret Behind the Silkiness of Chocolate (Part 1) Join Crystal Pharmatech for the Sino-American Pharmaceutical Professionals Association (SAPA) NE 26th Annual Conference Formulation Design and Development of Fixed Dose Combination Solid Oral Dosage Forms Sitemap Crystal Formulation Services, Formulation Tailor-made for Your Molecules Utility of Single Crystal in Form and Formulation Selection Optimal Preclinical Formulation Development ​Crystal Pharmatech will be in San Diego from June 3-6 at BIO International Convention Drug Delivery and Patient Centric Approaches to Drug Development  404 Candoo Enables the Successful Development of a BCS 4 Combo Drug Product Introduction to MicroED Technology and Solutions Salts Fun Sharing:The Story Between Ice Crystals and Frozen Foods (Part 3) Meet Crystal Pharmatech at Chinese Antibody Society 2024 Annual Conference Privacy Policy International Company Crystal Pharmatech Finds CCIT An Optimal Spot for First US Location Formulation Implications Pharmaceutical Solid-state Forms Meet Crystal Pharmatech at 15th Drug Discovery Strategic Summit (DDSS) Submission Successful! Crystal Pharmatech Triples Headquarters in Biobay, China, with More Floors and Labs Fun Sharing: The Relationship Between Ice Crystals and Frozen Foods (Part 1) Clinical Supply Meet Crystal Pharmatech at Sorption Symposium North America 2024 Taggg Xceleron and Crystal Pharmatech Announce Partnership to Improve Early Clinical Development Utilizing Absolute Bioavailability Trials and Solid-State Solutions CPHI North America - Meet Crystal Pharmatech at Booth 1441 Search Result Service Crystal Pharmatech Introduces Customized Service Packages for Customers Seeking Materials Science Approaches in Drug Discovery and Development Fun Sharing: The Story of Ice Crystals and Frozen Foods (Part 2) Meet Crystal Pharmatech at MIDD+ Boston 2024 Search Result Others Crystal Pharmatech Expands Leadership Team Case Study on Development and Production Applications of Amorphous Solid Dispersions - Hot Melt Extrusion Formulation Development: Fastest-to-FIH Without Sacrificing Quality Crystal Formulation Services(CFS)Opens New Formulation Development Center and Analytical R&D Lab in Suzhou, China event page Development and Production Application Case Study of Amorphous Solid Dispersions: Spray Drying DCAT WEEK: CMC Discussions Amorphous Solid Dispersion Technology and the Service Advantages of Crystal Pharmaceutical AAPS PharmSci360 - Meet Us at Booth # 2106 Candoo's Formulation Technology Platform Featured in the Drug Development & Delivery Journal ASD Column | Mastering Stable Art: Unveiling Key Factors Influencing Physical Stability of Amorphous Solid Dispersions Meet the Crystal Pharmatech formulation team next week at CPHI Crystal Pharmatech and the Future of Pharma at AAPS PharmSci 360 Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion ASD Column | How to Select Polymers in Hot-melt Extrusion Process? Crystal Pharmatech Raring to Go to ChemOutsourcing 2022 ASD Column | Understanding the ASD Preparation Methods and Selecting the Optimal Method for Solution Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer CPHI North america - Meet Us at Booth #530 Polymorphs, Solvatomorphs and Hydrate of Dabrafenib Crystal Bio Appoints Dr. Ye Gu as Co-founder, CTO, and Head of USA BD Shining Glory: Unveiling the "True Eye" behind the Veil of Drug Crystal Forms Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services Successfully Passed EU QP Audit Applications of Dynamic Moisture Adsorption in Crystal Research Meet Crystal Pharmatech at AAPS National Biotechnology Conference Application of Granularity Analysis in Crystal Typing Research Assessment of CQA in mRNA-LNP Modality DCAT Week 2025 A Brief Introduction to Amorphous Solid Dispersion Technology ADME Simulations: Insights into Bioavailability and Pharmacokinetics Understand ASD Manufacturing Strategies, Choose the Optimal One Parameter Sensitivity with GastroPlus Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023 Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1 Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes
Solid Form Screening Solid Form Developability Evaluation Absolute Structure Determination Crystallization Process Development The Purpose Behind Molecules to Medicine Repurposing Dexmedetomidine into an Oral Sleep-Enhancing Medication The Role of Collaboration in Optimizing the Development of HIF Inhibitors for the Treatment of Advan Mol2Med™ Integrated Services AAPS 2024 PHarmSCi 360 Concerned about mRNA -LNP Integrity during International Shipping? Improving the Manufacture of mRNA Biologics Home Formulation Development Solid Form Screening and Selection Our Company Talent Recruitment Case Study 1: Indinavir - Early Salt Form Change The Tiny-TIM System Technical Articles Solid Form Research Engineering Cocrystal Solubility and Streamlining Cocrystal Early Development The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C Biologics CMC Analytical Services High-Resolution Mass Spectrometry Crystal Pharmatech Formulation Forum News & Events Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes Unlocking the Power of AI in Pharmaceutical Development Formulation & Delivery US 2024 Concerned about mRNA -LNP Integrity during International Shipping? Analytical Techniques to Assess the mRNA 5' Cap Small Molecule Solid-State Characterization/FAST Conventional Oral Solid Dosage Forms Our History News Our Business Case Study 2: DPC 961 – Form Change On A Fast Track Compound Detecting and Avoiding Disappearing Polymorph Cases by Crystal Structure Prediction Presentations Preclinical and Tox Formulation Development Synthonic Engineering: Tools for the Rational Design of High Quality Pharmaceuticals Polymorphism of Drugs - Can We Exploit Physical Form in the Development of Low Solubility Molecules? Bioanalysis and Biomarker Services 2023-Mol2Med™ First-Time-Right Approach Webinar Series Date: 2:00-3:00 pm EDT, Wednesday, Watch on-demand
Developability Assessment Oral Solid Dosage Forms Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying CATUG and Crystal Bio Establish Strategic Partnership, Launching “CATUG-Crystal” Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services Characterization and Evaluation of Amorphous Solid Dispersion - Part 2 ADME Simulations: Insights into Bioavailability and Pharmacokinetics Utilizing Compaction Simulation for Advancing Oral Dosage Formulation Design Critical Quality Attribute (CQA) in Antibody Drug Conjugate (ADC) Modality The 16th Drug Discovery Strategic Summit (DDSS) - San Francisco Bioanalytical and Biomarker Services Single Crystal Growth & Structure Determination Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides Our People Events Case Study 3: Atorvastatin - Crystalline Form Change In Late Development Selecting the Right API Form and Formulation Instrumentation for Electron Diffraction, Applications, and Case Studies Case Studies Effective Development of API Crystallization Processes During Drug Development Efficient Preclinical Formulation Development for Poorly Soluble Compounds pKa/LogP/LogD Measurements Date: 2:00-3:00 pm EDT, Wednesday, Watch on-demand
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion) Dr. LianFeng Huang Joins Crystal Pharmatech as Chief Scientist Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1 Characterization and Evaluation of Amorphous Solid Dispersion-Part 2 Parameter Sensitivity with GastroPlus Critical Quality Attribute D0 Impact in ADC Modality SAPA Annual Conference (Gold Corporate Sponsorship) Crystal Bio Solutions Bio Analytics API Form and Solid-State Research Crystallization Development Mini-tablet Knowledge Hub Molecules-to-Medicine: Accelerating Drug Development through Collaboration PBPK in Preclinical/FIH Scenarios Whitepaper Case Study 4: Gatifloxacin - Crystalline Form Changes With A Licensed Compound Amorphous Solid Dispersions Using Thermodynamic Phase Maps in API Crystallization Process Design Pre-clinical Formulation Strategies Sponsored by Crystal Pharmatech Date: 2:00-3:00 pm EDT, Wednesday, Whatch on-demand
Stability and Solubility Studies Comprehensive Physicochemical Property Evaluation Pediatric Formulation (Mini-tablet) Crystal Formulation Services successfully passed the dual certification of GMP and GDP conducted by SGS Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions Assessment of CQA in mRNA-LNP Modality Overcoming Bioavailability Barrier to Deliver Protein Degraders 14th American Drug Delivery and Formulation Summit (Exhibit) Developability Assessment, Pre-formulation Study for IND Enabling Product Quality Analysis Additional Capabilities Chiral Separation Technology Our Partner Advanced Characterization: Tools for Accelerating Molecules to Medicine Tools for Accessing New Solid Forms Case Study 5: Lifecycle Management - Olanzapine - Crystalline Change From Free Acid to Salt Enabling Poorly Soluble Weak Bases for Improved Bioavailability: Why a Salt May Not be the Best Choice Integrated Phase and Formulation Selection to Support GLP Toxicology and First in Human Studies Sponsored by Crystal Pharmatech In-Silico PBPK Modeling and Simulation Industry Shift: FDA Goes Vegan? Date: 2:00-3:00 pm EDT, Wednesday,Watch on-demand
Crystallization Development Services Excipient Selection and Compatibility Studies Analytical Chemistry ASD Series Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying Overcoming Poor Solubility and Dissolution of Insoluble Molecules Patent Analysis of Resmetirom Sterility Assays in Drug/Device Manufacturing 2024 CASSS - Mass Spec Symposium Flow Cytometry About Us Pre-formulation Studies Formulations for PK/Efficacy/Tox Studies Crystallization and Spray Drying Process Development, Scale-Up, and Technology Transfer Case Study 6: Oxybutynin- Crystalline Change From Salt to Free Base Learn about Drug Eutectic Screening Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving the Important Milestone in Formulation Capability Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023 Biologics ChemOutsourcing 2024 Crystal Bio Webinar ELISpot Assays Solid-State NMR Analysis Resources Avoiding Drug Failures: Right First Time; Fast First Time Exploring the Pharmaceutical Solid State by Molecular Simulation Crystallization Process Method SMART Development of Pre-clinical Candidates Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services Formulation and Analytical Development Animal Dosing Vehicle Selection Detecting Low-Level Crystallinity in ASD-like Samples Using ssNMR Techniques Understand ASD Manufacturing Strategies, Choose the Optimal One Immuno-Oncology Summit 2024 - Meet Crystal Bio at Booth 15 Molecular Biology Clinical and Commercial Manufacturing Amorphous Solid Dispersions Careers Tools and Strategies for De-risking Rapid Drug Substance and Drug Product Development API Crystallization Crystal Pharmatech Returned to AAPS 2022 PharmSci 360 Fun Sharing: The Secret Behind the Silky Smoothness of Chocolate (Part 2) GMP Manufacturing A Brief Introdction to Amorphous Solid Dispersion Technology Amorphous Solid Dispersions: Two Heads Are Better Than One FIH-PMF-FMF Manufacturing The Bioprocessing Summit 2024 - Meet Crystal Bio at Booth T13 Contact Us Crystal Pharmatech and Particle Sciences Form a US-China Pharmaceutical CRO Partnership Advancements in Analytical Tools for API and DP Characterization Co-crystals Fun Sharing: The Secret behind the Silky Smooth Enjoyment of Chocolate (Part 3) Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs Meet Crystal Pharmatech at 2024 Controlled & Modified Drug Release Summit Assessment of Powder Segregation in Direct Compression (DC) Blends: Developing Predictive and PAT Tools Search Result Webinar Series Crystal Pharmatech Raises $10 Million to Accelerate Growth Solid Forms: The Good; The Bad; The Ugly Impact of Solid-state in Early Development Fun Sharing: The Secret Behind the Silkiness of Chocolate (Part 1) Join Crystal Pharmatech for the Sino-American Pharmaceutical Professionals Association (SAPA) NE 26th Annual Conference Formulation Design and Development of Fixed Dose Combination Solid Oral Dosage Forms Sitemap Crystal Formulation Services, Formulation Tailor-made for Your Molecules Utility of Single Crystal in Form and Formulation Selection Optimal Preclinical Formulation Development ​Crystal Pharmatech will be in San Diego from June 3-6 at BIO International Convention Drug Delivery and Patient Centric Approaches to Drug Development  404 Candoo Enables the Successful Development of a BCS 4 Combo Drug Product Introduction to MicroED Technology and Solutions Salts Fun Sharing:The Story Between Ice Crystals and Frozen Foods (Part 3) Meet Crystal Pharmatech at Chinese Antibody Society 2024 Annual Conference Privacy Policy International Company Crystal Pharmatech Finds CCIT An Optimal Spot for First US Location Formulation Implications Pharmaceutical Solid-state Forms Meet Crystal Pharmatech at 15th Drug Discovery Strategic Summit (DDSS) Submission Successful! Crystal Pharmatech Triples Headquarters in Biobay, China, with More Floors and Labs Fun Sharing: The Relationship Between Ice Crystals and Frozen Foods (Part 1) Clinical Supply Meet Crystal Pharmatech at Sorption Symposium North America 2024 Taggg Xceleron and Crystal Pharmatech Announce Partnership to Improve Early Clinical Development Utilizing Absolute Bioavailability Trials and Solid-State Solutions CPHI North America - Meet Crystal Pharmatech at Booth 1441 Search Result Service Crystal Pharmatech Introduces Customized Service Packages for Customers Seeking Materials Science Approaches in Drug Discovery and Development Fun Sharing: The Story of Ice Crystals and Frozen Foods (Part 2) Meet Crystal Pharmatech at MIDD+ Boston 2024 Search Result Others Crystal Pharmatech Expands Leadership Team Case Study on Development and Production Applications of Amorphous Solid Dispersions - Hot Melt Extrusion Formulation Development: Fastest-to-FIH Without Sacrificing Quality Crystal Formulation Services(CFS)Opens New Formulation Development Center and Analytical R&D Lab in Suzhou, China event page Development and Production Application Case Study of Amorphous Solid Dispersions: Spray Drying DCAT WEEK: CMC Discussions Amorphous Solid Dispersion Technology and the Service Advantages of Crystal Pharmaceutical AAPS PharmSci360 - Meet Us at Booth # 2106 Candoo's Formulation Technology Platform Featured in the Drug Development & Delivery Journal ASD Column | Mastering Stable Art: Unveiling Key Factors Influencing Physical Stability of Amorphous Solid Dispersions Meet the Crystal Pharmatech formulation team next week at CPHI Crystal Pharmatech and the Future of Pharma at AAPS PharmSci 360 Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion ASD Column | How to Select Polymers in Hot-melt Extrusion Process? Crystal Pharmatech Raring to Go to ChemOutsourcing 2022 ASD Column | Understanding the ASD Preparation Methods and Selecting the Optimal Method for Solution Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer CPHI North america - Meet Us at Booth #530 Polymorphs, Solvatomorphs and Hydrate of Dabrafenib Crystal Bio Appoints Dr. Ye Gu as Co-founder, CTO, and Head of USA BD Shining Glory: Unveiling the "True Eye" behind the Veil of Drug Crystal Forms Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services Successfully Passed EU QP Audit Applications of Dynamic Moisture Adsorption in Crystal Research Meet Crystal Pharmatech at AAPS National Biotechnology Conference Application of Granularity Analysis in Crystal Typing Research Assessment of CQA in mRNA-LNP Modality DCAT Week 2025 A Brief Introduction to Amorphous Solid Dispersion Technology ADME Simulations: Insights into Bioavailability and Pharmacokinetics Understand ASD Manufacturing Strategies, Choose the Optimal One Parameter Sensitivity with GastroPlus Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023 Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1 Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303